Premium
A retrospective data collection study in patients receiving two or more OZURDEX® injections for macular oedema secondary to retinal vein occlusion
Author(s) -
AUGUSTIN A,
HOLZ F,
HARITOGLOU C,
MEYER W,
LOMMATZSCH A,
BOPP S,
SCHEUERLE A,
MAIER M,
SEKUNDO W,
SANDNER D,
MALTMAN J,
SHIRLAW A,
HATTENBACH L
Publication year - 2012
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2012.4615.x
Subject(s) - medicine , intraocular pressure , retrospective cohort study , ophthalmology , glaucoma , confidence interval , occlusion , retinal vein , population , surgery , anesthesia , environmental health
Purpose This retrospective study was designed to investigate the re‐injection interval, efficacy and safety of OZURDEX® in routine clinical practice. Methods This analysis contains data from 87 patients from 10 sites in Germany who had received at least 2 OZURDEX® injections. Data was collected from the time of the patients’ first injection until 3 – 6 months following their latest OZURDEX® injection. Results The mean time to OZURDEX® re‐injection between 1st and 2nd treatments was 141 days (5.03 months) in the overall population. Mean time intervals for the BRVO and CRVO sub‐populations were 153 days (5.46 months) and 127 days (4.52 months) respectively. In the overall population, a mean LogMAR BCVA improvement from 0.68 to 0.51 was recorded following the last OZURDEX® injection (mean time of 11.0 weeks post‐injection). For BRVO, mean improvement was from 0.54 to 0.43 (mean time of 10.5 weeks post injection) and for CRVO, 0.83 to 0.58 (mean time of 11.5 weeks post injection). Reductions in central retinal thickness were also observed. Intraocular pressure measurements over 25mmHg were reported in 19.5% of patients. No glaucoma surgeries were reported. 5 patients underwent cataract surgery during the course of the study (4 had known lens opacity at baseline and opacity status data from the 5th was missing). Conclusion In this real life study, OZURDEX® was found to be safe and effective with repeat treatments. The mean re‐injection interval for RVO patients was 5.0 months.